These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 34262254)

  • 1. Real-World Outcomes in Diabetic Macular Edema for the 0.2 µg/Day Fluocinolone Acetonide Implant: Case Series from the Midlands, UK.
    Mushtaq B; Bhatnagar A; Palmer H
    Clin Ophthalmol; 2021; 15():2935-2943. PubMed ID: 34262254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of data characterizing the clinical effectiveness of the fluocinolone intravitreal implant (ILUVIEN) in patients with diabetic macular edema from the real world, non-interventional ICE-UK study and the FAME randomized controlled trials.
    Holden SE; Kapik B; Beiderbeck AB; Currie CJ
    Curr Med Res Opin; 2019 Jul; 35(7):1165-1176. PubMed ID: 30569759
    [No Abstract]   [Full Text] [Related]  

  • 3. Switching to intravitreal fluocinolone acetonide implant for refractory diabetic macular edema: 12- and 24-month results.
    Chronopoulos A; Chronopoulos P; Ashurov A; Korb C; Pfeiffer N; Hattenbach LO
    Eur J Ophthalmol; 2022 Jan; 32(1):443-449. PubMed ID: 33601897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluocinolone Acetonide Intravitreal Implant 190 μg (ILUVIEN®) in Vitrectomized versus Nonvitrectomized Eyes for the Treatment of Chronic Diabetic Macular Edema.
    Pessoa B; Coelho J; Correia N; Ferreira N; Beirão M; Meireles A
    Ophthalmic Res; 2018; 59(2):68-75. PubMed ID: 29248913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early adoption of the fluocinolone acetonide (FAc) intravitreal implant in patients with persistent or recurrent diabetic macular edema (DME).
    McCluskey JD; Kaufman PL; Wynne K; Lewis G
    Int Med Case Rep J; 2019; 12():93-102. PubMed ID: 31114396
    [No Abstract]   [Full Text] [Related]  

  • 6. The USER Study: A Chart Review of Patients Receiving a 0.2 µg/day Fluocinolone Acetonide Implant for Diabetic Macular Edema.
    Eaton A; Koh SS; Jimenez J; Riemann CD
    Ophthalmol Ther; 2019 Mar; 8(1):51-62. PubMed ID: 30560505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Three-year results from the Retro-IDEAL study: Real-world data from diabetic macular edema (DME) patients treated with ILUVIEN
    Augustin AJ; Bopp S; Fechner M; Holz F; Sandner D; Winkgen AM; Khoramnia R; Neuhann T; Warscher M; Spitzer M; Sekundo W; Seitz B; Duncker T; Ksinsik C; Höh H; Gentsch D
    Eur J Ophthalmol; 2020 Mar; 30(2):382-391. PubMed ID: 30884972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the clinical effectiveness of fluocinolone acetonide 190 µg intravitreal implant in diabetic macular edema: a comparison between study and fellow eyes.
    Currie CJ; Holden SE; Berni E; Owens DR
    Curr Med Res Opin; 2017 Oct; 33(sup2):19-31. PubMed ID: 28881143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Outcomes of Switching from Short- to Long-Term Intravitreal Corticosteroid Implant Therapy in Patients with Diabetic Macular Edema.
    Vaz-Pereira S; Castro-de-Sousa JP; Martins D; Prates Canelas J; Reis P; Sampaio A; Urbano H; Kaku P; Nascimento J; Marques-Neves C
    Ophthalmic Res; 2020; 63(2):114-121. PubMed ID: 31801148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diabetic macular edema outcomes in eyes treated with fluocinolone acetonide 0.2 µg/d intravitreal implant: real-world UK experience.
    El-Ghrably I; Steel DHW; Habib M; Vaideanu-Collins D; Manvikar S; Hillier RJ
    Eur J Ophthalmol; 2017 May; 27(3):357-362. PubMed ID: 28165610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the clinical effectiveness in routine practice of fluocinolone acetonide 190 µg intravitreal implant in people with diabetic macular edema.
    Holden SE; Currie CJ; Owens DR
    Curr Med Res Opin; 2017 Oct; 33(sup2):5-17. PubMed ID: 28881149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Case Series Investigating the Efficacy and Safety of Bilateral Fluocinolone Acetonide (ILUVIEN(®)) in Patients with Diabetic Macular Edema.
    Elaraoud I; Attawan A; Quhill F
    Ophthalmol Ther; 2016 Jun; 5(1):95-104. PubMed ID: 26885863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Case Series Investigating the Efficacy and Safety of Bilateral Fluocinolone Acetonide (ILUVIEN(®)) in Patients with Diabetic Macular Edema: 10 Eyes with 12 Months Follow-up.
    Elaraoud I; Quhill H; Quhill F
    Ophthalmol Ther; 2016 Jun; 5(1):105-9. PubMed ID: 27116231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluocinolone acetonide 0.19 mg intravitreal implant improves foveal thickness and reduces treatment burden for up to 1 year in eyes with persistent diabetic macular edema.
    Coney JM
    Int Med Case Rep J; 2019; 12():161-169. PubMed ID: 31213929
    [No Abstract]   [Full Text] [Related]  

  • 15. Evaluation of 0.2 µg/day fluocinolone acetonide (ILUVIEN) implant in a cohort of previously treated patients with diabetic macular oedema (DMO): a 36-month follow-up clinical case series.
    Ahmed M; Putri C; Quhill H; Quhill F
    BMJ Open Ophthalmol; 2020; 5(1):e000484. PubMed ID: 32656358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid Structural and Functional Improvements with the 0.19 mg Fluocinolone Acetonide Intravitreal Implant for Patients with DME and Low Visual Acuity: 6-Month Data from the UAE.
    Elbarky AM
    Clin Ophthalmol; 2020; 14():823-830. PubMed ID: 32214793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and safety outcomes of the 0.19 mg fluocinolone acetonide implant after prior treatment with the 0.7 mg dexamethasone implant in patients with diabetic macular edema.
    Singh P; Chedid A; Deuchler SK; Kohnen T; Müller M; Koch FH
    Int Med Case Rep J; 2018; 11():265-269. PubMed ID: 30410411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended real-world experience with the ILUVIEN® (fluocinolone acetonide) implant in the United Kingdom: 3-year results from the Medisoft® audit study.
    Bailey C; Chakravarthy U; Lotery A; Menon G; Talks J;
    Eye (Lond); 2022 May; 36(5):1012-1018. PubMed ID: 33972705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravitreal fluocinolone acetonide implant for chronic postoperative cystoid macular edema - two years results.
    Chronopoulos A; Chronopoulos P; Hattenbach LO; Ashurov A; Schutz JS; Pfeiffer N; Korb C
    Eur J Ophthalmol; 2022 Sep; ():11206721221124688. PubMed ID: 36062617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treating Diabetic Macular Oedema (DMO): real world UK clinical outcomes for the 0.19mg Fluocinolone Acetonide intravitreal implant (Iluvien™) at 2 years.
    Fusi-Rubiano W; Mukherjee C; Lane M; Tsaloumas MD; Glover N; Kidess A; Denniston AK; Palmer HE; Manna A; Morjaria R
    BMC Ophthalmol; 2018 Feb; 18(1):62. PubMed ID: 29486754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.